March 9, 2009 - The Ministry of Health for the Province of Quebec has awarded ZOLL Medical Corp. a contract valued in excess of $12 million to equip all ambulances in the Canadian province with the ZOLL E Series defibrillator, representing the first time the Province of Quebec will standardize its entire system to one model of defibrillator.

March 9, 2009 - Cytori Therapeutics Inc. completed enrollment in its APOLLO trial to evaluate the safety and feasibility of adipose tissue-derived stem and regenerative cells, processed with the company’s Celution System, in the treatment of severe heart attacks.

iNtuition is TeraRecon's new, unified workflow platform, which delivers the best possible solution for advanced image management in an enterprise and an efficient way to manage workflow once the CT data leaves the MDCT scanner.

March 9, 2008 - Biomaterials company SyntheMed Inc. has received FDA approval of its pre-market approval (PMA) application for REPEL-CV Adhesion Barrier for use in pediatric cardiac surgery patients.

March 9, 2009 - A study, presented at the 21st European Congress of Radiology, comparing the performance of TeraRecon’s Aquarius iNtuition solution with a competitor’s solution for assessment of Cardiac CT studies, concluded that TeraRecon’s solution increased performance with less operator interaction.

March 6, 2009 – VectraCor Inc. submitted its 510(k) application to the FDA in December for a new technology to derive 22-lead ECG function from only five electrodes

March 6, 2009 - Transoma Medical Inc.’s Sleuth AT wireless, automated implantable cardiac monitoring system was implanted in its first U.S. patient on March 2 at the Ohio State University Medical Center.

Researchers at the Section of Cardiology, Department of Medicine, University of Chicago Hospitals said their findings, published in the March 1 issue of the American Journal of Cardiology, Vol. 103, Issue 5, suggest SPECT perfusion imaging should be conducted on patients who have abnormal heart rate recovery (HRR) on routine exercise treadmill testing.

March 6, 2009 - Atritech Inc. will release PROTECT AF trial results on WATCHMAN LAA closure technology comparing the device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation.

March 6, 2009 – New research published in the March edition of the HeartRhythm Journal reveals that black and Hispanic patients who were eligible for cardiac resynchronization therapy with defibrillator (CRT-D) were less likely to receive therapy than eligible white patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now